Introduction {#s1}
============

Recently, growing attention has been addressed to nanocarriers for Indocyanine green (ICG) delivery with the purpose of overcoming some of its current limitations and to expand its possible applications in cancer diagnosis and treatment (Wang et al., [@B73]). ICG is a widely investigated near infrared (NIR) fluorescent agent, approved for clinical use by the Food and Drug Administration (FDA) in the 1950s (Landsman et al., [@B34]; Alius et al., [@B3]). Over the past decade, NIR optical imaging using ICG has become determining for a variety of applications, including lymphangiography, intra-operative lymph node (LN) identification, tissue perfusion, detection of vital structures, and tumor imaging (Fox and Wood, [@B16]; Starosolski et al., [@B66]). ICG displays several advantages thoroughly verified during its long clinical use: it is easy to use, cost-effective, radiation-free, and safe. Although ICG fluorescent imaging represents a promising medical tool, its application remains limited due to the intrinsic issues related to ICG degradation and rapid blood clearance (Muckle, [@B47]; Saxena et al., [@B57]; Zheng et al., [@B84]). Therefore, many studies suggest that the exploitation of ICG-based nano-formulations (micelles, polymeric nanoparticles, silica nanoparticles, and liposomes) could boost the efficacy, specificity, and biosafety of this imaging agent for potential oncological applications (Yan et al., [@B77]; Egloff-Juras et al., [@B15]).

Properties of ICG {#s2}
=================

ICG is an amphiphilic tricarbocyanine dye used in the biomedical field for almost six decades for different purposes (Schaafsma et al., [@B58]; Hill et al., [@B22]). ICG is an anionic, water-soluble, and fluorescent molecule with a molecular weight of 751 Da and that displays absorption and fluorescence emission in the NIR wavelength region (Zhao et al., [@B80]). These properties allow deep penetration of the signal and minimize interference of tissues\' autofluorescence, making it suitable for bio-imaging uses (Wang et al., [@B74]; Yuan et al., [@B79]). Moreover, since it is an FDA-approved dye, well studied in its already known clinical applications, its introduction to new clinical applications is greatly simplified (Alander et al., [@B1]; Valente et al., [@B71]). Additionally, due to its photosensitizing properties, ICG can be used to generate oxygen species (ROS) or heat, aiming to destroy cancer cells in photodynamic therapy (PDT) and photothermal therapy (PTT) (Dolmans et al., [@B13]; Kuo et al., [@B33]). Despite these compelling properties, the application of ICG is restricted due to its concentration-dependent aggregation, quick degradation, and poor photostability. Furthermore, its non-specific binding to plasma proteins determines a relatively short circulation half-life, and its non-specific targeting remains a limitation (Kirchherr et al., [@B31]; Yaseen et al., [@B78]).

ICG as an NIR Fluorescent Contrast Agent: Clinical Applications {#s3}
===============================================================

As previously mentioned, ICG has an excellent safety profile and, following injection of a clinical standard dose (0.1--0.5 mg/kg), immediately interacts with plasma proteins, acting as an excellent vascular agent for evaluating both the blood perfusion and lymphatic drainage (Alford et al., [@B2]; Marshall et al., [@B43]; Boni et al., [@B8]). Once excited at the wavelength of about 820 nm, ICG emits a fluorescent signal detectable by specific scopes and cameras to allow identification of anatomical structures where the dye localizes (Luo et al., [@B40]; Daskalaki et al., [@B11]). Indeed, ICG is used in intraoperative angiography for assessment of superficial eye vessels and in the evaluation of coronary artery bypass grafts, peripheral vascular disease, and solid organ transplantation (Reuthebuch et al., [@B54]; Sekijima et al., [@B59]; Desai et al., [@B12]; Kang et al., [@B28],[@B29]; Baillif et al., [@B6]). Moreover, since, once injected intravenously, ICG is excreted exclusively via the liver, it is used to assess hepatic function (Daskalaki et al., [@B11]). In addition to these applications, ICG is employed in NIR fluorescence image-guided oncologic surgery with the purpose of identifying structures that need to be resected (e.g., tumor tissue, lymph nodes) and spared, contributing to support the surgeon\'s decision-making process (Boni et al., [@B8]; Baiocchi et al., [@B7]).

Of note, NIR fluorescence imaging via ICG can provide real-time identification of tumor margins and affected lymph nodes (LN) in breast and skin cancers, improving local control of the disease and allowing a more conservative surgery (Sevick-Muraca et al., [@B60]; Fujiwara et al., [@B17]; Murawa et al., [@B48]). Sentinel LN (SLN) mapping is important to detect involved LN and is required for cancer staging, prognosis prediction, and therapy selection (Schaafsma et al., [@B58]; Wang et al., [@B73]). Here, ICG is injected near the tumor and flows via lymph circulation to LN, displaying them when lit with excitation light (Tanaka et al., [@B68]; Alander et al., [@B1]; Wishart et al., [@B75]; Verbeek et al., [@B72]). ICG-NIR fluorescence imaging has been applied also to intraoperative tumor detection in order to ensure a total tumor resection (Gotoh et al., [@B18]; Onda et al., [@B49]; Rossi et al., [@B56]). Indeed, exploiting ICG hepatic clearance and the enhanced permeability and retention (EPR) effect, liver tumors could be identified (Ishizawa et al., [@B26]; Huang et al., [@B24]).

To date, the application of ICG as an NIR fluorescence imaging agent in oncology is an active and promising area, but it also has limitations. Aside from the problems inherent with some of its physicochemical properties, ICG is a non-targeted or extremely low targeted tracer, which greatly precludes its application for specific cancer imaging (Landsman et al., [@B34]; Marshall et al., [@B43]; Wang et al., [@B73]; Egloff-Juras et al., [@B15]).

ICG-NPs and Cancer: Preclinical Studies {#s4}
=======================================

Recently, the development of multifunctional ICG-NPs, offering both diagnostic and therapeutic solutions in cancer, has captured the attention of researchers (Han et al., [@B21]). To overcome the limitations previously discussed, several ICG-NPs have been proposed and tested, both *in vitro* and *in vivo* (Liu et al., [@B38]; ZhuGe et al., [@B86]), displaying increased circulation time and improved ICG optical properties and achieving tumor-specific accumulation. Many advantages derive from their use: combining or encapsulating it to/into NPs results in the extension of ICG half-life. Additionally, functionalization with specific cancer-related antibodies may result in preferential accumulation of ICG at the tumor site. Furthermore, ICG-NPs may be useful to limit ICG aggregation and photodegradation as well as to improve its stability in aqueous solutions (Ishizawa et al., [@B26]; Liu et al., [@B39]; ZhuGe et al., [@B86]). ICG has been loaded or conjugated to a variety of nanostructures, such as polymer-based NPs, lipid-based NPs, and silica NPs with different surface modifications and functionalization strategies ([Figure 1A](#F1){ref-type="fig"}). Among the plethora of ICG-NPs for different targets and applications, we focused on the following main applications for cancer treatment: PDT and PTT (i), *in vivo* imaging and image-guided surgery (ii), and multimodal therapy (iii) ([Figure 1B](#F1){ref-type="fig"}). A summary of all significant examples of ICG-NPs developed for these applications has been inserted in [Table 1](#T1){ref-type="table"}.

![**(A)** Some examples of the ICG-NPs obtained with different materials and conjugation techniques. **(B)** Main applications of ICG-NPs in cancer treatment.](fchem-08-00535-g0001){#F1}

###### 

Summary of all significant examples of ICG nanoparticles studied *in vivo*.

  **ICG-NPs: preclinical research**                                                                                                                                                                                                                                                                   
  ------------------------------------------------------------------------------------------------ ------------------------------------- ------------------------------------------ ------------------------------------------- --------------------------------------------------------------------- ----------------------------
  Calcium phosphate nanoparticles                                                                  ICG encapsulation                     Breast cancer                              Fluoroprobing                               Improved half life Improved photostability Biocompatibility           Altinoglu et al., [@B5]
  Water-responsive phospholipid-calcium-carbonate hybrid nanoparticle                              ICG loading doxorubicin loading       Breast cancer                              PTT                                         Good tissue penetration Decreased metastatic areas                    Liu et al., [@B38]
  Super carbonate apatite nanoparticles                                                            ICG loading                           Colorectal adenocarcinoma                  PDT                                         Fluorescence enhancement Significant tumor growth retardation         Tamai et al., [@B67]
  Hydrophobic superparamagnetic iron oxide nanoparticles                                           ICG loading doxorubicin coating       Glioblastoma                               MRI imaging Chemotherapy                    BBB crossing Accumulation at the tumor site                           Shen et al., [@B62]
  Graphene oxide hybrid nano-composites                                                            Electrostatic interaction with ICG    Colorectal adenocarcinoma                  PTT                                         Citotoxicity in cancer cells only                                     Sharker et al., [@B61]
  Polyamidoamine (PAMAM)-coated silica nanoparticles                                               ICG coating                           Sentinel lymph nodes                       Sentinel lymph node imaging                 Facilitatation of sentinel lymph node biopsy procedures               Tsuchimochi et al., [@B69]
  PL-PEG-mAb nanoparticles                                                                         ICG-PEG conjugation                   Glioblastoma Breast cancer                 PTT Imaging                                 Good targeting Tumor reduction                                        Zheng et al., [@B84]
  PLGA-PEG-R837 nanoparticles                                                                      ICG encapsulation                     Breast cancer                              PTT Immunotherapy                           Great antitumor effect Strong immune-memory effect                    Chen et al., [@B10]
  PEG-PCL-C3 hybrid nanoparticles                                                                  ICG-PEG conjugation                   Oral squamous cell carcinoma               PTT PDT                                     *In vivo* safety Active role in reducing tumor volume                 Ren et al., [@B53]
  Levan nanoparticles                                                                              ICG encapsulation                     Breast cancer                              Imaging                                     Selective targeting of cancer cells                                   Kim et al., [@B30]
  Silk fibroin nanoparticles cross-linked by proanthocyanidins                                     ICG encapsulation                     Glioblastoma                               PTT                                         Stable photothermal properties Decrease of tumor volume               ZhuGe et al., [@B86]
  Silk fibroin nanoparticles                                                                       ICG encapsulation                     Glioblastoma                               PTT                                         Inhibition of tumor growth                                            Xu et al., [@B76]
  Hyaluronic acid nanoformulation                                                                  ICG entrapment                        Pancreatic cancer                          Tumor detection                             Safe contrast agent                                                   Qi et al., [@B52]
  Hyaluronic acid nanoformulation                                                                  ICG entrapment                        Breast cancer                              Image-guided surgery                        Good contrast enhancement                                             Hill et al., [@B22]
  Hyaluronic acid nanogels                                                                         ICG entrapment                        Breast cancer                              Imaging                                     Improved imaging of metastatic lymph nodes                            Mok et al., [@B45]
  Polymer-lipid nanoparticles                                                                      ICG encapsulation                     Pancreatic cancer                          PTT                                         Suppression of tumor growth                                           Zhao et al., [@B80]
  Mannosylated liposomes                                                                           ICG encapsulation                     Sentinel lymph nodes                       Sentinel lymph node imaging                 Increased liposomal stability Good optical properties                 Jeong et al., [@B27]
  Liposomes                                                                                        Lipid-bound ICG                       Healthy organism                           Imaging                                     Fluorescence enhancement                                              Kraft and Ho, [@B32]
  Liposomes                                                                                        ICG-iDOPE incorporation               Glioblastoma                               PDT                                         Suppression of tumor growth                                           Shibata et al., [@B65]
  Gold nanorod\@liposome core--shell nanoparticles                                                 ICG loading                           Liver cancer                               Photoacoustic tomography Surgery Guidance   Prolonged half-life Preoperative detection of liver cancer            Guan et al., [@B20]
  Micelles                                                                                         ICG-PEG conjugation                   Lung carcinoma                             PTT                                         Tumor detection Inhibition of tumor growth                            Li et al., [@B36]
  Micelles                                                                                         ICG/retinal loading                   Murine breast cancer                       PTT                                         Suppression of tumor growth                                           Zhu et al., [@B85]
  Lactosomes (micelles assembled from block copolymers)                                            ICG loading                           Metastatic lymph nodes in gastric cancer   PDT Imaging                                 Selective accumulation in metastatic lymph nodes                      Tsujimoto et al., [@B70]
  [^\*^](#TN1){ref-type="table-fn"}Phospholipid nanoprobes Folic acid-phospholipid nanoparticles   ICG-PEG conjugation                   Glioblastoma Breast cancer                 PTT Imaging                                 Selective imaging of cancer cells Selective killing of cancer cells   Zheng et al., [@B83]
  Folate-targeted lipid nanoparticles                                                              ICG/oxygen loading                    Ovarian cancer                             PTT PDT Imaging                             Good targeting Increased PDT efficacy                                 Liu et al., [@B39]
  Folic acid-targeted nanoparticles                                                                ICG loading                           Breast cancer                              PTT                                         Significant targeting to MCF-7 tumors Tumor growth inhibition         Zheng et al., [@B82]
  HDL nanoparticles                                                                                ICG encapsulation                     Murine breast cancer                       PTT PDT                                     Deep tumor penetration Enhanced tumor necrosis                        Sheng et al., [@B63]
  Human ferritin                                                                                   Photosensitizer encapsulation         Glioblastoma                               PDT                                         High phototoxicity in tumors Normal tissue left unaffected            Zhen et al., [@B81]
  BSA nanoparticles                                                                                ICG coating artemisin encapsulation   Epidermal carcinoma                        PTT PDT                                     Synergistic photo-chemotherapy                                        Ma et al., [@B42]
  Human serum albumin                                                                              ICG adsorption                        Murine breast cancer                       PTT PDT                                     Tumor margin detenction Tumor eradication without regrowth            Sheng et al., [@B64]
  [^§^](#TN2){ref-type="table-fn"}Human serum albumin                                              ICG adsorption                        Breast cancer                              Sentinel lymph node mapping                 Clinical trial                                                        Hutteman et al., [@B25]

*in vitro research only*.

*clinical trial*.

PDT is an emerging, minimally invasive cancer treatment based on the production of ROS in response to a source of light, the presence of oxygen and a photosensitizer (i.e., ICG) (ZhuGe et al., [@B86]). Although this option seems promising for many cancers (Gross et al., [@B19]; Ritch and Punnen, [@B55]), selective delivery of the photosensitizers at target tissues/cells remains insufficient for successful clinical use (Zhen et al., [@B81]). Since PDT could generate an antitumor immune response, ICG-loaded liposomes were studied in combination with NIR irradiation, demonstrating suppression of brain tumor growth and suggesting the potential application for the treatment of tumors near the brain surface (Shibata et al., [@B65]). Super carbonate apatite-ICG NPs improved ICG uptake in tumor cells and its antitumor effect in a colorectal xenograft model, serving as a useful vehicle for ICG-based PDT (Tamai et al., [@B67]). Also, hydroxyethyl starch-oleic acid ICG-NPs exhibited excellent stability and efficient ROS generation and increased cellular uptake and tumor accumulation compared to free ICG (Hu et al., [@B23]).

In addition to PDT, PTT also arose as a promising approach for cancer treatment by using NIR-light to generate heat and achieve tumor ablation (Li et al., [@B35]). The main challenge with PTT is that heat could also damage the healthy surrounding tissue and fail to eradicate metastatic cells. Several NPs with excellent NIR light absorption have been developed as PTT agents, including gold, copper, carbon NPs, and NIR dyes (Lv et al., [@B41]). Also, ICG has been exploited in a multitude of NPs as a PTT agent (Doughty et al., [@B14]). ICG-conjugated micelles have been investigated for breast and lung cancer treatment displaying increased circulation time, accurate tumor targeting, and efficient PTT effect compared with free ICG (Li et al., [@B36]; Zhu et al., [@B85]). Another work proposed the functionalization with folic acid to achieve accumulation on MCF-7 breast cancer cells, obtaining a significant tumor growth inhibition (Zheng et al., [@B82]). A formulation of pH-responsive polymeric nano-complexes of graphene oxide and ICG (Sharker et al., [@B61]) was effective in providing selective sensitivity to tumor environment and tumor regression, confirming its clinical usefulness. Also, in studies with ICG-loaded polymer-lipid NPs against pancreatic cancer (Zhao et al., [@B80]) and silk fibroin NPs addressing glioblastoma (Xu et al., [@B76]), the main advantages observed, compared to free ICG, were an extended circulation time and *in vivo* stability, together with the ability to specifically target cancer cells (Sheng et al., [@B63]).

An assortment of ICG-NPs also has been developed for bioimaging applications as agents for tumor identification. Since early detection is crucial for the prompt diagnosis and successful treatment of cancer, the benefits of using NPs as vector for ICG to the tumor site would be significant. ICG-incorporating liposomes provide enhanced visualization of the popliteal LN and downstream LN, detected across 1.5 cm of muscle tissue, and free ICG only enables 0.5 cm detection (Kraft and Ho, [@B32]). Hyaluronic acid (HA) NPs allow contrast enhancement (Hill et al., [@B22]), and levan NPs display good targeted imaging of breast tumors and the suitability to encapsulate hydrophobic drugs (Kim et al., [@B30]). ICG-HA--derived NPs improve the NIR signal for intraoperative detection of pancreas and splenic metastasis compared to ICG (Qi et al., [@B52]), and also nanogels display good performance in targeted imaging of cancers and LN metastases in addition to the feasible drug-encapsulation in their hydrophobic core (Mok et al., [@B45]). ICG-doped calcium phosphate NPs display increased deep-tissue penetration (Altinoglu et al., [@B5]). Another promising strategy involves its effectiveness as a photoacoustic-fluorescence imaging probe in liver cancer detection (Guan et al., [@B20]). Overall, all the considered formulations display a non-toxic safety profile, a longer circulation time, and a higher tumor accumulation than free ICG. This would provide the potential to increase the completeness of surgery and the chances of a better outcome. Furthermore, different ICG-NPs were suggested as contrast agents for SLN mapping. Mannosilated ICG-liposomes show improved stability and fluorescence signal by exploiting their specific recognition by macrophages, making it a good agent for SLN and LN imaging (Jeong et al., [@B27]). Silica NPs loaded with technetium and ICG improve LN detection in real time although further studies are necessary to assess the appropriate dose (Tsuchimochi et al., [@B69]), and ICG-loaded lactosomes provide an improved LN detection and a inhibited growth upon PDT treatment (Tsujimoto et al., [@B70]). The only example tested in the clinic concerns the use of ICG adsorbed to human serum albumin (ICG:HSA) aiming to improve detection and better retention in the SLN after intradermal injection. However, this trial performed on breast cancer patients showed no advantage of ICG:HSA for SLN mapping (Hutteman et al., [@B25]).

Very often, the applications described above have been used in combination to obtain better therapeutic results. Indeed, many authors consider the use of ICG for imaging-guided PTT, allowing simultaneously tumor detection and eradication. ICG-PL-PEG NPs were investigated *in vitro* for cell imaging and selective PTT, proving to be an interesting multifunctional system (Zheng et al., [@B83]), and Liu and coworkers provide a synergistic strategy for both offering contrast enhancement and tumor growth reduction against ovarian cancer (Liu et al., [@B39]). Furthermore, the successful application of HSA-ICG NPs for *in vivo* imaging and tumor margin detection following PDT/PTT synergic phototherapy has been reported (Sheng et al., [@B64]). Many authors also insist on the strength of the synergistic combination of PTT and PDT to obtain better therapeutic results (Ren et al., [@B53]; Sheng et al., [@B63]; Zhu et al., [@B85]).

Moreover, since monotherapy, either PTT or PDT usually suffers from incomplete tumor killing, leading potentially to tumor relapse (Ma et al., [@B42]); a combination with chemotherapy could optimize the cancer treatment. In this context, chemotherapy drugs combined with phototherapy have been studied. Doxorubicin has been exploited in superparamagnetic iron oxide NPs with ICG displaying good imaging ability, showing accumulation in the tumor site and high antitumor efficacy with few side effects in glioma-bearing rats (Shen et al., [@B62]). Phospholipid-calcium-carbonate NPs loaded with doxorubicin and ICG demonstrate strong tumor-homing properties and a synergistic effect in terms of tumor growth reduction (Liu et al., [@B38]). Regarding cancer immunotherapy, the photothermal ablation of tumors with immune-adjuvant ICG-NPs, seems promising in activating immune responses potentially applicable for metastasis treatment (Chen et al., [@B10]). Overall, multimodal therapies appear to enhance the therapeutic effects and prevent possible recurrences.

ICG-NPs: Opportunities, Limitations and Possible Impacts in Oncology {#s5}
====================================================================

Implementing a plethora of different ICG-NPs makes the comparison between them especially difficult. Overall, the most promising strategies are related to actively targeted ICG-NPs, but there is a significant gap in outcomes between preclinical cancer models and their translation into clinical practice. As previously discussed, several recent studies are focusing on the development of ICG-NPs, aiming to exploit the advantages of ICG in order to further increase cancer therapies.

First, ICG-NPs could be effective in improving the already existing imaging techniques, either by prolonging ICG half-life or by selectively addressing the molecule to cancer cells only; that could be particularly relevant when trying to identify metastases as well as being useful to early detection of cancer cells in case of relapse. The chance to use NPs-ICG as drugs to directly treat tumors represents an additional advantage. By exploiting the ability of ICG to both generate heat and ROS in response to NIR, ICG-NPs could be used for PTT, PDT, or both in order to elicit antitumor response (Han et al., [@B21]; Liu et al., [@B39]). Indeed, the accumulation of ICG in tumor cells and their exposure to light, determines a localized increase in temperature that causes cell damage by apoptosis and necrosis, resulting in tumor ablation (Melamed et al., [@B44]; Pérez-Hernández et al., [@B50]). In the meantime, in the presence of oxygen, light-activated ICG also generates ROS, leading to cell death and tissue destruction (Allison and Moghissi, [@B4]). Nevertheless, recent studies are quite misleading about the application of PTT and PDT, which rely on different therapeutic mechanisms. However, when ICG is used, both effects could be achieved although with a distinct tumor cell--killing contribution by each (Liu et al., [@B37]). More clarity about which strategy is being referred to is necessary since, through ICG, one thing does not exclude the other, and the related side effects should be considered as well. Both PTT and PDT are promising for the treatment of several malignancies; however, it is important to understand which aspect to target to design the appropriate NPs (Pinto and Pocard, [@B51]).

The first concern is about immunogenicity. Although it is common opinion that ICG itself is not toxic and that ICG-NPs can be selectively targeted to the tumor, it is still uncertain if other tissues could be affected by the treatment. NPs must not elicit an immune response and demonstrate not to be toxic for the organism.

A second issue is obvious: cancer is not a single disease. Tumors may be solid or not, have clear or irregular borders, spread in easily reachable districts or in hard-to-treat areas. Additionally, similar tumors may have different density, vasculature, and tumor microenvironment. Here, the ability of ICG-NPs to penetrate into the tumor is unclear, thus making it hard to decide if ICG-NPs should be addressed to primary tumors and metastases or used as adjuvants after surgery (Tsujimoto et al., [@B70]; Sheng et al., [@B63]). Research on ICG-NPs should develop the optimal strategy for real clinical applications on each disease instead of just developing NPs that prove to be effective at a preclinical stage but are difficult to translate into clinical trials.

Regarding the multitude of developed ICG-NPs, one fact is evident: every group focuses on the NP type they are used to working with as well as on the tumor model they know better ([Table 1](#T1){ref-type="table"}). Such an approach is both useful and harmful. On the one hand, long-term expertise in developing a specific NP could be addressed to the production of highly effective ICG-NPs; on the other hand, several cancer models should be tested to evaluate the efficacy of the proposed treatment in different contexts. Focusing on a single model could be limiting if the purpose is to design a consistent model for the development of new therapies. Options to design ICG-NPs are unlimited, and many could be adjusted to target different tumors (Han et al., [@B21]). NPs can be further enriched by conjugation with other molecules: monoclonal antibodies, fluorescence probes and drugs in order to maximize the antitumor effect of the ICG-NPs (Zheng et al., [@B83]; Sheng et al., [@B64]; Ma et al., [@B42]). Here, given that the enhancement of targeting is crucial to prevent damage of healthy tissues, NPs should be selectively directed to the tumor, either inserting targeting molecules or by exploiting the intrinsic ability of some carriers to bind cancer.

Despite all the advantages deriving from ICG-NPs and the huge amount of solutions proposed so far, a pool of clinical applications have not been outlined yet, thus making it impossible to determine which ones have the potential to become actual drugs. The answer is not one and only: different nanoparticles could be used to treat different tumors, and different molecules could be attached to improve their selectivity. Therefore, developing dozens of different ICG-NPs is not of help in finding the best alternatives that could be eventually tested in clinical trials.

On top of everything, when discussing the potentiality of ICG-NPs in therapy, an uncomfortable yet necessary question should be raised about the costs of clinical trials involving NPs: developing such molecules, especially when they are combined with chemotherapeutic drugs and/or patented monoclonal antibodies, has been proved to be extremely expensive, thus limiting the possibility to produce high amounts of molecules to be used in clinical trials.

Discussion {#s6}
==========

In conclusion, the potential of ICG-conjugated NPs is undeniable, mostly because they could possibly be directed toward several cancer types with incredibly high specificity (Bozkulak et al., [@B9]; Montazerabadi et al., [@B46]). Indeed, they could overcome some of the limitations of current treatments, especially regarding tumors that are poorly accessible by drugs or hard to treat, and they could also limit the side effects usually associated to conventional therapies (Montazerabadi et al., [@B46]). However, obtaining specific cell targeting as well as maintaining high drug concentration at the tumor site remain the main challenges as they are both necessary conditions for the implementation of ICG-NPs--based imaging, PTT, and PDT. This is the reason why the currently known ICG-NPs have not successfully reached the translation into clinics so far. Therefore, an improved active targeting is required for a major impact on human health. Moreover, since the penetration depth of light in tissues could be limited, even with NIR lasers, endoscope-based clinical devices equipped with a laser may be demanded in order to reach successful outcomes in clinical practice (Chen et al., [@B10]). Some sort of consensus should also be achieved about the most promising formulations and the real aims of the proposed interventions: PTT, PDT, and imaging are not interchangeable terms, and more precision is required when deciding which therapies would be worth testing. In addition, before trying to develop new ICG-NPs, the economic impact of a potential trial involving such NPs must be carefully considered. Expertise and deep knowledge in the field are mandatory, but feasibility will eventually determine if a promising molecule will ever be translated into an actual therapy.
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